Gene signature driving invasive mucinous adenocarcinoma of the lung

EMBO Molecular Medicine

Volumn 9, Issue 4, 2017, Pages 462-481

  Guo, Minzhe ^a,b   Tomoshige, Koichi ^a   Meister, Michael ^c   Muley, Thomas ^c   Fukazawa, Takuya ^d   Tsuchiya, Tomoshi ^e   Karns, Rebekah ^a   Warth, Arne ^f   Fink Baldauf, Iris M ^a   Nagayasu, Takeshi ^e   Naomoto, Yoshio ^d   Xu, Yan ^a   Mall, Marcus A ^f   Maeda, Yutaka ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b University of Cincinnati   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

FOXA3; IMA; MUC5AC 5B; SPDEF; VTCN1

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3GAMMA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; K RAS PROTEIN; MUCIN; MUCIN 3; MUCIN 5AC; MUCIN 5B; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B7-H4 GENE; BREAST CANCER; CONTROLLED STUDY; CRISPR CAS SYSTEM; DIGESTIVE SYSTEM CANCER; FOXA3 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE REGULATORY NETWORK; GENETIC MARKER; HNF4A GENE; HUMAN; HUMAN CELL; KRAS GENE; LUNG ADENOCARCINOMA; MOUSE; MUC3 GENE; MUC5AC GENE; MUC5B GENE; NONHUMAN; PANCREAS CANCER; PD-L1 GENE; PROTEIN SYNTHESIS; SPDEF GENE; TRANSGENIC MOUSE; TUMOR INVASION; VTCN1 GENE; ANIMAL; COLLOID CARCINOMA; GENE EXPRESSION PROFILING; LUNG TUMOR; PATHOLOGY;

ADENOCARCINOMA, MUCINOUS; ANIMALS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC;

EID: 85014133712     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201606711     Document Type: Article

References (65)

1. Ahn SH, Shah YM, Inoue J, Morimura K, Kim I, Yim S, Lambert G, Kurotani R, Nagashima K, Gonzalez FJ et al (2008) Hepatocyte nuclear factor 4alpha in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm Bowel Dis 14: 908–920
2. Allen T, van Tuyl M, Iyengar P, Jothy S, Post M, Tsao MS, Lobe CG (2006) Grg1 acts as a lung-specific oncogene in a transgenic mouse model. Cancer Res 66: 1294–1301
3. Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J, Jeselsohn R, Lim E, Chi D, Fu X et al (2013) PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. Cancer Cell 23: 753–767
4. Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511: 543–550
5. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M et al (2016) MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352: 227–231
6. Chen G, Korfhagen TR, Xu Y, Kitzmiller J, Wert SE, Maeda Y, Gregorieff A, Clevers H, Whitsett JA (2009) SPDEF is required for mouse pulmonary goblet cell differentiation and regulates a network of genes associated with mucus production. J Clin Invest 119: 2914–2924
7. Chen G, Korfhagen TR, Karp CL, Impey S, Xu Y, Randell SH, Kitzmiller J, Maeda Y, Haitchi HM, Sridharan A et al (2014) Foxa3 induces goblet cell metaplasia and inhibits innate antiviral immunity. Am J Respir Crit Care Med 189: 301–313
8. Cheng XH, Black M, Ustiyan V, Le T, Fulford L, Sridharan A, Medvedovic M, Kalinichenko VV, Whitsett JA, Kalin TV (2014) SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene. PLoS Genet 10: e1004656
9. Choi YH, Lee SN, Aoyagi H, Yamasaki Y, Yoo JY, Park B, Shin DM, Yoon HG, Yoon JH (2011) The extracellular signal-regulated kinase mitogen-activated protein kinase/ribosomal S6 protein kinase 1 cascade phosphorylates cAMP response element-binding protein to induce MUC5B gene expression via D-prostanoid receptor signaling. J Biol Chem 286: 34199–34214
10. Ding X, Yang Y, Han B, Du C, Xu N, Huang H, Cai T, Zhang A, Han ZG, Zhou W et al (2014) Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation. PLoS One 9: e95307
11. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK (2003) Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 63: 4626–4631
12. Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, Ortiz-Cuaran S, Peifer M, Bos M, Daßler J et al (2014) CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov 4: 415–422
13. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249–3262
14. Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, Suvà ML, Bernstein BE (2016) Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529: 110–114
15. Fletcher MN, Castro MA, Wang X, de Santiago I, O'Reilly M, Chin SF, Rueda OM, Caldas C, Ponder BA, Markowetz F et al (2013) Master regulators of FGFR2 signalling and breast cancer risk. Nat Commun 4: 2464
16. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372: 2018–2028
17. Ghadersohi A, Sood AK (2001) Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin Cancer Res 7: 2731–2738
18. Ghadersohi A, Odunsi K, Zhang S, Azrak RG, Bundy BN, Manjili MH, Li F (2008) Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer 123: 1376–1384
19. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 18: 1611–1618
20. Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA (2007) Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 67: 4219–4226
21. Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ, Brugge JS (2005) Novel role for PDEF in epithelial cell migration and invasion. Cancer Res 65: 11572–11580
22. Hata A, Katakami N, Fujita S, Kaji R, Imai Y, Takahashi Y, Nishimura T, Tomii K, Ishihara K (2010) Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol 5: 1197–1200
23. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563–567
24. Hirsch FR, Suda K, Wiens J, Bunn PA Jr (2016) New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 388: 1012–1024
25. Jeon YK, Park SG, Choi IW, Lee SW, Lee SM, Choi I (2015) Cancer cell-associated cytoplasmic B7-H4 is induced by hypoxia through hypoxia-inducible factor-1α and promotes cancer cell proliferation. Biochem Biophys Res Commun 459: 277–283
26. Kaur S, Kumar S, Momi N, Sasson AR, Batra SK (2013) Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol 10: 607–620
27. Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, Degenhardt J, Mayba O, Gnad F, Liu J et al (2015) A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol 33: 306–312
28. Kreda SM, Davis CW, Rose MC (2012) CFTR, mucins, and mucus obstruction in cystic fibrosis. Cold Spring Harb Perspect Med 2: a009589
29. Kufe DW (2009) Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9: 874–885
30. Kunii R, Jiang S, Hasegawa G, Yamamoto T, Umezu H, Watanabe T, Tsuchida M, Hashimoto T, Hamakubo T, Kodama T et al (2011) The predominant expression of hepatocyte nuclear factor 4α (HNF4α) in thyroid transcription factor-1 (TTF-1)-negative pulmonary adenocarcinoma. Histopathology 58: 467–476
31. Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, Oh S, Shin JG, Yao S, Chen L et al (2006) Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 580: 755–762
32. Lee YS, Lee JW, Jang JW, Chi XZ, Kim JH, Li YH, Kim MK, Kim DM, Choi BS, Kim EG et al (2013) Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 24: 603–616
33. Leong SR, Liang WC, Wu Y, Crocker L, Cheng E, Sampath D, Ohri R, Raab H, Hass PE, Pham T et al (2015) An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Mol Pharm 12: 1717–1729
34. Li B, Dewey CN (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12: 323
35. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, Sharpe AH (2003) Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 33: 2706–2716
36. Loke P, Allison JP (2003) PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 100: 5336–5341
37. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15: 550
38. Maeda Y, Hunter TC, Loudy DE, Davé V, Schreiber V, Whitsett JA (2006) PARP-2 interacts with TTF-1 and regulates expression of surfactant protein-B. J Biol Chem 281: 9600–9606
39. Maeda Y, Chen G, Xu Y, Haitchi HM, Du L, Keiser AR, Howarth PH, Davies DE, Holgate ST, Whitsett JA (2011) Airway epithelial transcription factor NK2 homeobox 1 inhibits mucous cell metaplasia and Th2 inflammation. Am J Respir Crit Care Med 184: 421–429
40. Maeda Y, Tsuchiya T, Hao H, Tompkins DH, Xu Y, Mucenski ML, Du L, Keiser AR, Fukazawa T, Naomoto Y et al (2012) Kras (G12D) and Nk2–1 haploinsufficiency induce mucinous adenocarcinoma of the lung. J Clin Invest 122: 4388–4400
41. Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB et al (2014) Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346: 1373–1377
42. Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA et al (2008) Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA 105: 20852–20857
43. Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, Shimada Y, Ogiwara H, Watanabe S et al (2014) Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res 20: 3087–3093
44. Noah TK, Lo YH, Price A, Chen G, King E, Washington MK, Aronow BJ, Shroyer NF (2013) SPDEF functions as a colorectal tumor suppressor by inhibiting β-catenin activity. Gastroenterology 144: 1012–1023.e6
45. Park KS, Korfhagen TR, Bruno MD, Kitzmiller JA, Wan H, Wert SE, Khurana Hershey GK, Chen G, Whitsett JA (2007) SPDEF regulates goblet cell hyperplasia in the airway epithelium. J Clin Invest 117: 978–988
46. Perl AK, Zhang L, Whitsett JA (2009) Conditional expression of genes in the respiratory epithelium in transgenic mice: cautionary notes and toward building a better mouse trap. Am J Respir Cell Mol Biol 40: 1–3
47. Rodabaugh KJ, Mhawech-Fauceglia P, Groth J, Lele S, Sood AK (2007) Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors. Int J Gynecol Pathol 26: 10–15
48. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD et al (2011) A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364: 1503–1512
49. Serresi M, Gargiulo G, Proost N, Siteur B, Cesaroni M, Koppens M, Xie H, Sutherland KD, Hulsman D, Citterio E et al (2016) Polycomb repressive complex 2 is a barrier to KRAS-driven inflammation and epithelial-mesenchymal transition in non-small-cell lung cancer. Cancer Cell 29: 17–31
50. Shin H, Liu T, Manrai AK, Liu XS (2009) CEAS: cis-regulatory element annotation system. Bioinformatics 25: 2605–2606
51. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR et al (2015) Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5: 860–877
52. Smyth MJ, Ngiow SF, Ribas A, Teng MW (2016) Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13: 143–158
53. Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S et al (2013) Nk2–1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell 50: 185–199
54. Sóñora C, Mazal D, Berois N, Buisine MP, Ubillos L, Varangot M, Barrios E, Carzoglio J, Aubert JP, Osinaga E (2006) Immunohistochemical analysis of MUC5B apomucin expression in breast cancer and non-malignant breast tissues. J Histochem Cytochem 54: 289–299
55. Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, Kasyapa CS, Geradts J (2007) Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Hum Pathol 38: 1628–1638
56. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545–15550
57. Sugano M, Nagasaka T, Sasaki E, Murakami Y, Hosoda W, Hida T, Mitsudomi T, Yatabe Y (2013) HNF4α as a marker for invasive mucinous adenocarcinoma of the lung. Am J Surg Pathol 37: 211–218
58. Sutherland KD, Song JY, Kwon MC, Proost N, Zevenhoven J, Berns A (2014) Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci USA 111: 4952–4957
59. Thomas-Chollier M, Darbo E, Herrmann C, Defrance M, Thieffry D, van Helden J (2012b) A complete workflow for the analysis of full-size ChIP-seq (and similar) data sets using peak-motifs. Nat Protoc 7: 1551–1568
60. Thomas-Chollier M, Herrmann C, Defrance M, Sand O, Thieffry D, van Helden J (2012a) RSAT peak-motifs: motif analysis in full-size ChIP-seq datasets. Nucleic Acids Res 40: e31
61. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244–285
62. Turner DP, Findlay VJ, Kirven AD, Moussa O, Watson DK (2008) Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Mol Biol Cell 19: 3745–3757
63. Valque H, Gouyer V, Gottrand F, Desseyn JL (2012) MUC5B leads to aggressive behavior of breast cancer MCF7 cells. PLoS One 7: e46699
64. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W et al (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol 9: R137
65. Zhang X, Choi PS, Francis JM, Imielinski M, Watanabe H, Cherniack AD, Meyerson M (2016) Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet 48: 176–182